Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ingulli, E.
Right arrow Articles by Tejani, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ingulli, E.
Right arrow Articles by Tejani, A.

Journal of the American Society of Nephrology, Vol 3, 254-259, Copyright © 1992 by American Society of Nephrology

REGULAR ARTICLES

Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose- dependent manner in children with nephrotic syndrome

E Ingulli and A Tejani
Children's Hospital, Boston, MA.

In order to identify possible markers of cyclosporin A (CSA) efficacy, the use of CSA (6 mg/kg) in 47 children with refractory nephrotic syndrome was reviewed. Response was defined as remission of proteinuria within 2 months. Before CSA administration, nonresponders (N = 13) were found to have more proteinuria (6 versus 3 g/24 h; P less than 0.03) and higher serum creatinine levels (0.9 versus 0.6 mg/dL; P less than 0.03) compared with responders (N = 34). Also, a markedly elevated serum cholesterol level (545 versus 312 mg/dL; P less than 0.001) was noted among nonresponders. Logistic regression analysis of all three parameters isolated serum cholesterol (P less than 0.01) as the only significant predictor of CSA nonresponsiveness. Discriminate analysis identified serum cholesterol to predict 97% of responders and 77% of nonresponders (P less than 0.0005) to conventional CSA doses. The CSA whole-blood trough HPLC levels were subtherapeutic among nonresponders (71 ng/mL) compared with responders (162 ng/mL) (P less than 0.001). Thus, a high serum cholesterol level may prevent the achievement of therapeutic CSA blood levels with conventional doses. On the basis of this, seven of the nonresponders were re-treated by titration of the CSA dose (10 to 14 mg/kg) with their serum cholesterol level. Their mean highest trough CSA level was 286 ng/mL. Five patients responded within 2 months. No elevation in serum creatinine or evidence of nephrotoxicity on repeat biopsy was seen after 2 months of therapy in all seven patients. It was concluded that severe hypercholesterolemia in nephrotic syndrome patients necessitates the titration of the CSA dose with the serum cholesterol level to achieve remission.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Meyrier
Nephrotic focal segmental glomerulosclerosis in 2004: an update
Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2437 - 2444.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Daimon, T. Saga, M. Nakayama, Y. Nomura, H. Chikaki, K. Dan, and I. Koni
Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis
Nephrol. Dial. Transplant., February 1, 2000; 15(2): 235 - 238.
[Full Text] [PDF]

Home page
 NEJMHome page
S. R. Orth and E. Ritz
The Nephrotic Syndrome
N. Engl. J. Med., April 23, 1998; 338(17): 1202 - 1211.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673